ARVO

New therapies needed for allergy symptoms, quality of lifeHalf of patients with ocular allergies report experiencing symptoms year-round. While nearly all of them take eye drops to treat their symptoms, the majority report limited or no effect from over-the-counter drops, according to a new survey. The results suggest that new treatment approaches would improve both symptoms and quality of life.
ARVO calls for applications for Dr. David L. Epstein AwardAt its 2017 general business meeting in May, the Association for Research in Vision and Ophthalmology (ARVO) welcomed a new president, Claude F. Burgoyne, MD, FARVO. Dr. Burgoyne, a glaucoma clinician and surgeon, is senior scientist, Van Buskirk Chair for Ophthalmic Research, and director of the Optic Nerve Head Research Laboratory at Devers Eye Institute, Portland, OR. He also serves as clinical professor of ophthalmology at Oregon Health and Sciences University, Eugene.
ARVO 2017 showcases vision research advancesAdvances in presbyopia, dry eye and allergy, and age-related macular degeneration filled this year’s meeting of the Association for Research in Vision and Ophthalmology.
ARVO 2017 awards in spotlightAs eye and vision researchers gather this month for the 2017 meeting of the Association for Research in Vision and Ophthalmology (ARVO), four members will be recognized for their contributions to ophthalmology and vision research with a 2017 ARVO Achievement Award and lecture.
Researchers, scientists flock to East Coast for ARVO 2017The annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) continues to explore new cities after spending many years in Fort Lauderdale, FL. This year’s installment will be held May 6 to 11 at the Baltimore Convention Center, and will feature the theme “Global Connections in Vision Research,” in recognition of the fact that successful science requires strong global connections--among researchers, across disciplines, and between generations.
Study tracks clinical use of dexamethasone implant for DMEA 6-month analysis from the REINFORCE study of the dexamethasone intravitreal implant Ozurdex found an average of one- to two-line vision gains and no new safety concerns.
IL-1 receptor inhibitor fails on ocular itching endpointIsunakinra, an interleukin-1 signaling inhibitor designed for topical ophthalmic administration, did not meet the primary endpoint in a phase III clinical trial for the treatment of moderate-to-severe allergic conjunctivitis.
Getting ready for ARVO 2017: New president, special OCT issueLearn about the latest updates from The Association for Research in Vision and Ophthalmology for 2017 and beyond.
10 things you may have missed at ARVO
10 things you may have missed at ARVOFrom blueberries for dry eye, to advances in "robotic" vision, here are some highlights from ARVO 2016.
ARVO 2015 Making powerful connections in vision research, online networkingMore than 11,000 clinicians and researchers will gather in Denver to learn more about leading eye and vision research at the 2015 meeting of the Association for Research in Vision and Ophthalmology.